E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult endogenous hyperinsulinemic hypoglycaemia |
|
E.1.1.1 | Medical condition in easily understood language |
Low glucose levels caused by excess insulin secretion in adults |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10077227 |
E.1.2 | Term | Hyperinsulinemic hypoglycemia |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Comparison of 68Ga-NODAGA-exendin-4 with 68Ga-DOTATOC PET/CT in order to determine the sensitivity of the new imaging method |
|
E.2.2 | Secondary objectives of the trial |
- Comparison of 68Ga-NODAGA-exendin-4 with standard imaging (eg. triple phase CT, MRI and endoscopic ultrasound)
- Calculating the organ- and effective dose of 68Ga-NODAGA-exendin 4 on the basis of quantification of serial PET images.
- Impact on clinical management of GLP-1R imaging, e.g. possible use of GLP-1R imaging as standard for preoperative imaging in AHH.
- Calculating and comparing the interobserver variability of 68Ga-NODAGA-exendin 4 PET/CT combined with triple phase CT or MRI
- Comparing imaging parameters (SUVmax), intraoperative findings, histology and GLP-1/sst2 receptor expression by in vitro autoradiography on frozen tissue samples |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Biochemically proven endogenous hyperinsulinemic hypoglycemia: neuroglycopenic symptoms in the fasting state with low plasma glucose, inappropriately high serum insulin and C-peptide concentrations
Signed informed consent
Standard imaging not older than 8 weeks. This includes a triple-phase CT or MRI, somatostatin receptor imaging (68Ga-DOTATOC PET) and endocopic ultrasound (EUS). Protocols that should be followed for these procedures can be found in the annex. |
|
E.4 | Principal exclusion criteria |
Breast feeding
Pregnancy or the wish to become pregnant within 6 months
Calculated creatinine clearance below 40ml/min
Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions)
Age < 18 years
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Comparison of sensitivity between 68Ga-NODAGA-exendin 4 and conventional imaging such as triple phase CT, MRI, F-18-DOPA, and 68Ga-DOTATOC in adult patients with biochemically proven endogenous hyperinsulinemic hypoglycemia. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Calculation of the organ- and effective dose of 68Ga-NODAGA-exendin 4
Assessing the impact on clinical management of GLP-1R imaging
Calculation and comparison of the interobserver variability of 68Ga-NODAGA-exendin 4 PET/CT and EUS combined with triple phase CT or MRI
Comparison of imaging parameters (SUVmax), intraoperative findings, histology and GLP-1/sst2 receptor expression in vitro autoradiography on frozen tissue samples |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Evaluated at the time of imaging except for clinical management and histology and other tissue related end points that will be evaluated postoperatively |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |